Ratings by Wells Fargo (Chris M. Carey)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/8/2026 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/12/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/9/2026 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Kezar Life Sciences | KZR | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 10/15/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/8/2025 | Cabaletta Bio Inc. | CABA | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/8/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/10/2025 | Ascendis Pharma | ASND | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/1/2025 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/19/2024 | Kezer Life Sciences | KZR | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2024 | Immunovant | IMVT | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2024 | Cabaletta Bio Inc. | CABA | Downgrade | Equal Weight (Overweight) |
2.29 (3.19) |
39.3% | Details | |
| 11/15/2024 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2024 | Kezer Life Sciences | KZR | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/7/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 9/4/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/11/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2024 | Immunovant | IMVT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 4/18/2024 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 3/22/2024 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/15/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 2/23/2024 | Morphic Therapeutic | MORF | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2024 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2023 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 12/7/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 11/14/2023 | Kezer Life Sciences | KZR | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/10/2023 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2023 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/27/2023 | Immunovant | IMVT | Maintain | Overweight (N/A) |
|
Details | ||
| 9/6/2023 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2023 | Kezer Life Sciences | KZR | Downgrade | Equal Weight (Overweight) |
2.01 (7.29) |
262.69% | Details | |
| 7/24/2023 | Immunovant | IMVT | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2023 | Kezer Life Sciences | KZR | Maintain | Overweight (N/A) |
|
Details | ||
| 4/18/2023 | Prometheus Biosciences Inc | RXDX | Downgrade | Equal Weight (Overweight) |
114.01 (199.92) |
75.35% | Details | |
| 3/10/2023 | Hydrofoam | HYFM | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/2/2023 | Rhythm Pharmaceuticals | RYTM | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2023 | Kezer Life Sciences | KZR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2023 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2023 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 1/3/2023 | Hydrofoam | HYFM | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/3/2023 | GrowGeneration | GRWG | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/3/2023 | Immunovant | IMVT | Upgrade | Overweight (Equal Weight) |
17.41 (38.79) |
122.8% | Details | |
| 11/8/2022 | Morphic Therapeutic | MORF | Maintain | Overweight (N/A) |
|
Details | ||
| 11/8/2022 | Immunovant | IMVT | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/7/2022 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 9/14/2022 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/6/2022 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2022 | Morphic Therapeutic | MORF | Maintain | Overweight (N/A) |
|
Details | ||
| 8/3/2022 | Hydrofoam | HYFM | Maintain | Equal Weight (N/A) |
|
Details | ||
| 6/28/2022 | Kezer Life Sciences | KZR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2022 | Hydrofoam | HYFM | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/13/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/13/2022 | Kezer Life Sciences | KZR | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2022 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2022 | Morphic Therapeutic | MORF | Maintain | Overweight (N/A) |
|
Details | ||
| 3/23/2022 | Horizon Therapeutics | HZNP | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/3/2022 | Ascendis Pharma | ASND | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2022 | Hydrofoam | HYFM | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/1/2022 | GrowGeneration | GRWG | Maintain | Equal Weight (N/A) |
|
Details | ||
| 1/13/2022 | GrowGeneration | GRWG | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/8/2021 | Rhythm Pharmaceuticals | RYTM | New Coverage | Overweight (N/A) |
9.26 (114.17) |
1132.94% | Details | |
| 12/8/2021 | Prometheus Biosciences Inc | RXDX | New Coverage | Overweight (N/A) |
29.92 (199.92) |
568.18% | Details | |
| 12/8/2021 | Morphic Therapeutic | MORF | New Coverage | Overweight (N/A) |
47.72 (56.99) |
19.43% | Details | |
| 12/8/2021 | Immunovant | IMVT | New Coverage | Equal Weight (N/A) |
7.65 (38.79) |
407.06% | Details | |
| 12/8/2021 | Horizon Therapeutics | HZNP | New Coverage | Overweight (N/A) |
98.56 (116.30) |
18% | Details | |
| 12/8/2021 | Cabaletta Bio Inc. | CABA | New Coverage | Overweight (N/A) |
10.68 (3.19) |
-70.13% | Details | |
| 12/8/2021 | Ascendis Pharma | ASND | New Coverage | Overweight (N/A) |
136.64 (274.50) |
100.89% | Details | |
| 12/8/2021 | Arena Pharma | ARNA | New Coverage | Overweight (N/A) |
50.07 (99.98) |
99.68% | Details | |
| 12/8/2021 | Kezer Life Sciences | KZR | New Coverage | Overweight (N/A) |
13.44 (7.29) |
-45.76% | Details | |
| 12/8/2021 | Apellis Pharmaceuticals | APLS | New Coverage | Overweight (N/A) |
40.03 (41.03) |
2.5% | Details | |
| 12/7/2021 | GrowGeneration | GRWG | New Coverage | Equal Weight (N/A) |
15.17 (1.47) |
-90.31% | Details | |
| 12/7/2021 | Hydrofoam | HYFM | New Coverage | Equal Weight (N/A) |
29.15 (0.79) |
-97.29% | Details |
